Evidence map›Paper›PMID 30853312›Full record

ArticleJournal of autoimmunity2019

AS101 ameliorates experimental autoimmune uveitis by regulating Th1 and Th17 responses and inducing Treg cells.

So Jin Bing, Itay Shemesh, Wai Po Chong, Reiko Horai, Yingyos Jittayasothorn, Phyllis B Silver, Benjamin Sredni, Rachel R Caspi

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of autoimmunity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. CD4International journal of molecular sciences · 2021
    Review
  16. Review
  17. Article
  18. Tregs in Autoimmune Uveitis.Advances in experimental medicine and biology · 2021
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

So Jin BingLaboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Itay ShemeshC.A.I.R. Institute, Safdié AIDS and Immunology Research Center, Mina & Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 52900, Israel.
Wai Po ChongLaboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Reiko HoraiLaboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Yingyos JittayasothornLaboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Phyllis B SilverLaboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Benjamin SredniC.A.I.R. Institute, Safdié AIDS and Immunology Research Center, Mina & Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 52900, Israel. Electronic address: srednib@biu.ac.il.
Rachel R CaspiLaboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, 20892, USA. Electronic address: caspir@mail.nih.gov.
National Institutes of Health · USBar-Ilan University · ILNational Eye Institute · US

Funding

Genetic, Cellular and Molecular Mechanisms in Autoimmunity to RetinaZIAEY000184 · NEI · NATIONAL EYE INSTITUTE · PI CASPI, RACHEL R. · 2009 to 2025
$51.7M
T-CELL LINES AND CLONES IN UVEITAZ01EY000184 · NEI · NATIONAL EYE INSTITUTE · PI CASPI, RACHEL R. · 1985 to 2008
$6.6M
Intramural NIH HHS Z01 EY000184Intramural NIH HHS Z99 EY999999
6 · The paper itself

Abstract

AS101 is an organotellurium compound with multifaceted immunoregulatory properties that is remarkable for its lack of toxicity. We tested the therapeutic effect of AS101 in experimental autoimmune uveitis (EAU), a model for human autoimmune uveitis. Unexpectedly, treatment with AS101 elicited Treg generation in vivo in otherwise unmanipulated mice. Mice immunized for EAU with the retinal antigen IRBP and treated with AS101 developed attenuated disease, as did AS101-treated recipients of retina-specific T cells activated in vitro. In both settings, eye-infiltrating effector T cells were decreased, whereas regulatory T (Treg) cells in the spleen were increased. Mechanistic studies in vitro revealed that AS101 restricted polarization of retina-specific T cells towards Th1 or Th17 lineage by repressing activation of their respective lineage-specific transcription factors and downstream signals. Retina-specific T cells polarized in vitro towards Th1 or Th17 in the presence of AS101 had impaired ability to induce EAU in naïve recipients. Finally, AS101 promoted differentiation of retina-specific T cells to Tregs in vitro independently of TGF-β. We conclude that AS101 modulates autoimmune T cells by inhibiting acquisition and expression of effector function and by promoting Treg generation, and suggest that AS101 could be useful as a therapeutic approach for autoimmune uveitis.

Indexed as

AnimalsAutoimmune DiseasesDisease Models, AnimalEthylenesMiceMice, TransgenicTh17 CellsTh1 CellsT-Lymphocytes, RegulatoryUveitisammonium trichloro(dioxoethylene-O,O'-)tellurateEthylenesAS101Experimental autoimmune uveitisRegulatory T cellTh17 cell

Identifiers

PMID30853312
PMCPMC6513711
OpenAlexW2920900903

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.